Countries trying to shift to clean energy while also preparing for extreme weather and other impacts in a warmer world will ...
Discover key Q3 2025 earnings insights for Arcturus Therapeutics: pipeline progress, regulatory updates, and financial outlook.
18hon MSN
ProFrac outlines $100M cost savings initiative and targets $200M capital raise amid volatile Q3
Discover ProFrac's Q3 2025 earnings highlights—cost-saving strategies, dedicated fleet focus, and future outlook amid sector volatility.
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback